L-TheaninevsNALT

L-Theanine (gamma-glutamylethylamide) crosses the blood-brain barrier via the large neutral amino acid transporter (LAT1/SLC7A5) and exerts anxiolytic effects through multiple pathways. It increases GABA synthesis by serving as a substrate for glutamate decarboxylase (GAD), elevating inhibitory tone without directly binding GABA-A receptors — avoiding sedation. It modulates serotonin by increasing tryptophan hydroxylase (TPH2) activity and raises dopamine levels in the prefrontal cortex via inhibition of dopamine reuptake. L-Theanine antagonizes glutamate binding at AMPA and kainate receptor subtypes (GluA1-4, GluK1-5), reducing excitatory neurotransmission and excitotoxicity risk. This glutamate antagonism, combined with increased GABA, drives the characteristic increase in alpha brain wave power (8-14 Hz) in the posterior parietal and occipital cortex — the EEG signature of relaxed alertness. When co-administered with caffeine, L-theanine attenuates caffeine-induced increases in blood pressure and anxiety by modulating sympathetic nervous system activation through alpha-2 adrenergic receptor pathways, while caffeine's dopaminergic and adenosine-blocking effects on focus and attention are preserved.

NALT (N-acetyl L-tyrosine) is deacetylated by aryl acylamidase in the gut and liver to release L-Tyrosine. Tyrosine is hydroxylated to L-DOPA by tyrosine hydroxylase (TH) — the rate-limiting step in catecholamine synthesis, requiring tetrahydrobiopterin as cofactor. L-DOPA is decarboxylated by aromatic L-amino acid decarboxylase (AADC) to dopamine; dopamine is converted to norepinephrine by dopamine beta-hydroxylase (DBH), and norepinephrine to epinephrine by phenylethanolamine N-methyltransferase (PNMT). Under stress or sleep deprivation, catecholamine stores in noradrenergic and dopaminergic neurons deplete rapidly. Supplemental tyrosine provides substrate to maintain synthesis when demand exceeds supply, supporting prefrontal cortex function and working memory.